Sophiris Bio Inc. (SPHS)

Oncology Corporate Profile

Stock Performance

2.3900
0.0000

3 Month Stock History Chart

HQ Location

1258 Prospect Street
La Jolla, CA 92037

Company Description

Sophiris Bio Inc. is a biopharmaceutical company developing PRX302, a clinical-stage, targeted therapy for the treatment of urological diseases. PRX302 is in Phase 3 clinical development for the treatment of the symptoms of benign prostatic hyperplasia (BPH) and is designed to be as efficacious as pharmaceuticals, less invasive than the surgical interventions, and without the sexual side effects seen with existing treatments. PRX302 is also currently in a Phase 2a proof of concept study for the treatment of localized low to intermediate risk prostate cancer.

Website: http://www.sophirisbio.com/

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
topsalysin / PRX302prostate-specific antigen (PSA) inhibitorProstate cancerII

View additional information on product candidates here »

Source: http://www.sophirisbio.com/

Recent News Headlines

8/21/2017 06:22 am

8/21/2017 06:22 am

8/21/2017 06:22 am

8/21/2017 06:22 am

8/17/2017 06:19 am

8/17/2017 06:19 am

8/17/2017 06:19 am

8/17/2017 06:19 am

8/15/2017 06:19 am

8/15/2017 06:19 am

8/10/2017 12:19 pm

8/10/2017 12:19 pm

8/10/2017 12:19 pm

8/10/2017 12:19 pm

6/23/2017 12:19 pm

6/23/2017 12:19 pm

6/8/2017 06:19 am

5/23/2017 12:19 pm

5/18/2017 12:19 pm

5/15/2017 12:19 pm

5/15/2017 12:19 am

Sophiris Bio to Present at 16th Annual Needham Healthcare Conference

3/29/2017 08:00 pm

[PR Newswire] - SAN DIEGO and VANCOUVER, British Columbia, March 29, 2017 /PRNewswire/ -- Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"), a clinical late-stage biopharmaceutical company developing topsalysin (PRX302) for the treatment of patients with urological diseases, today announced that Randall E. Woods, president and chief executive officer, will present a corporate overview at the 16th Annual Needham Healthcare Conference. The presentation will be webcast live and can be accessed through the Investor Relations page at www.sophirisbio.com.

Sophiris Bio Reports Fourth Quarter and Full Year 2016 Financial Results and Key Corporate Highlights

3/27/2017 01:00 pm

[PR Newswire] - SAN DIEGO and VANCOUVER, British Columbia, March 27, 2017 /PRNewswire/ -- Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"), a clinical late-stage biopharmaceutical company ...

Topsalysin Data from Successful Phase 2a Localized Prostate Cancer Study to be Presented at the 32nd European Association of Urology Congress

3/23/2017 08:00 pm

[PR Newswire] - SAN DIEGO and VANCOUVER, British Columbia, March 23, 2017 /PRNewswire/ -- Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"), a clinical late-stage biopharmaceutical company ...